Edwards Lifesciences Corporation (EW) SEC Filings & Earnings Calls

Loss of strategy executive but extended transition period mitigates disruption.

“Retirement planned for mid-2027 with consulting role through end of 2027.”

Investment impairment risk

“In March 2026, as a result of the carrying amount of investments not being recoverable, the Company recognized a $123.6 million loss on impairment, including $11.1 million of accrued interest, during the six months ended June 30, 2026.” · word for word

Tax litigation risk

“us-gaap:InternalRevenueServiceIRSMember ew:FinalNoticesOfProposedAdjustmentOneMember us-gaap:TaxYear2018Member 2026-04-01 2026-06-30” · word for word

California tax law change creates $188.2M valuation allowance against deferred tax assets

“California budget legislation enacted June 29, 2026 includes new permanent limitation on business tax credits; company recorded $188.2M valuation allowance”

Impairment losses on variable interest entity investments

“Loss on impairment of $123.6M in Q1 2026 and $40.0M in Q2 2026 related to VIE investments”

Potential dilution from increased share reserve for equity awards.

“7,000,000 additional shares”

Significant litigation expenses

“Certain litigation expenses $37.1 million for Q1 2026 vs $10.9 million for Q1 2025.”

Impairment of investments in VIEs

“Loss on impairment $123.6 million for Q1 2026 vs $0 for Q1 2025.”

Operating cash flow decline

“Net cash provided by operating activities $43.8 million for Q1 2026 vs $280.4 million for Q1 2025.”

Gross margin pressure from FX and manufacturing expansion for new therapies.

“Gross profit margin 78.0% vs 78.7% prior year, driven by weakening dollar and additional manufacturing expenses.”

Regulatory risk from CMS NCD reconsideration for TAVR; potential impact on reimbursement.

“CMS is conducting the process to reconsider the National Coverage Determination (NCD) for TAVR.” · word for word

Relative TSR underperformance risk

“our relative TSR was -7.95% points below the median and, in line with our pay-for-performance philosophy, the 2022 PBRSUs were forfeited in their entirety with no payout.” · word for word

Key executive retention risk

“Mr. Wood resigned as an officer and employee of the Company, effective September 1, 2025. ... In connection with the transition of Mr. Ullem from his role as the Company’s Chief Financial Officer by midyear 2026, we entered into a transition agreement with Mr. Ullem on November 4, 2025” · word for word

Shareholder dilution risk from equity plan

“The proposed amendment and restatement would increase the aggregate number of shares of our common stock available for issuance under the Long-Term Stock Program by an additional 7,000,000 shares” · word for word

Hospital capacity constraints limiting procedure volumes

“We have in the past and are continuing to experience constrained procedure volumes and sales for our products because more products, including Edwards’ own products, are competing for the same facilities and staffing within hospitals.” · word for word

Reimbursement risk

“Changes in current coverage and reimbursement levels could have an adverse effect on market demand and our pricing flexibility.” · word for word

Competitive pressure from Medtronic and Abbott

“In TAVR, our primary competitors include Medtronic plc (“Medtronic”) and Abbott Laboratories (“Abbott”).” · word for word

SG&A increase to 38.4% of sales from 35.5% may pressure margins if revenue growth slows.

“Selling, general and administrative expenses in the fourth quarter were $603 million, or 38.4% of sales, compared to 35.5% of sales in the prior year.” · word for word

Gross margin slightly declined year-over-year; need to monitor cost trends.

“Gross profit margin was 78.1%, or 78.3% adjusted, compared to 78.9%, or 79.0% adjusted, in the same period last year.” · word for word

Antitrust risk materialized; acquisition blocked.

“FTC injunction blocked acquisition of JenaValve”

Litigation risk

“Certain litigation expenses $90.4 million for the three months ended September 30, 2025, compared to $10.8 million for the same period in 2024.”

Regulatory risk (FTC blocking acquisition)

“On August 6, 2025, the United States Federal Trade Commission moved to block the proposed acquisition of JenaValve, alleging anticompetitive concerns.” · word for word

Impairment risk

“In August 2025, the Company recorded a $40.0 million charge related to the full impairment of certain developed technology assets.” · word for word

Competitor exit in Europe provided modest sales contribution, but market rebalancing may be temporary.

“In Europe, the exit of a competitor resulted in a rebalancing of the market and a modest contribution to Edwards’ sales” · word for word

CFO transition could introduce uncertainty, but planned transition mitigates risk.

“planned transition will enable continuity and a smooth transfer of responsibilities” · word for word